Executive Summary
NASA issued a single $109.2M delivery order to Caltech for JPL FFRDC operations and EMIT mineral dust project, with $90.3M outlayed and $125.4M ceiling including options, neutral for public equities due to nonprofit recipient. Long-term commitment through 2028 signals stable NASA space R&D funding via FFRDCs. Monitor $16.2M unexercised options and future task orders for potential upside realization.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior New Federal Contractors digest from March 15, 2026.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Long 10-year performance period to 2028 with full obligation dependent on future NASA task orders
Opportunities (1)
- ◆
$16.2M unexercised options to reach $125.4M ceiling, plus potential for additional NASA task orders via JPL FFRDC sponsorship
Sector Themes (1)
- ◆
Non-competed delivery order under NAICS 541715/PSC AR22 reinforces NASA's long-term reliance on Caltech-operated JPL for space science missions like EMIT.
Watch List (1)
- 👁
{"entity"=>"Caltech/JPL NASA Contracts", "reason"=>"$109.2M obligation with $16.2M options and task order dependency signals potential for further space R&D funding through 2028", "trigger"=>"Option exercises or new delivery orders exceeding $125.4M ceiling"}
Get daily alerts with 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: New Federal Contractors
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals